Discovery of new ways to modulate estrogen actions through estrogen receptor is always exciting because of the importance of estrogen and ERs in many human diseases. In this dissertation, we report our discovery of the cross-talk between SF-hERRβ and hERs and the mechanism of this cross-talk. We found that SF-hERRβ is able to repress the transcriptional activities of hERα and hERβ in various cell lines. This inhibitory effect of SF-hERRβ is not through alterations of estradiol binding to hERs. SF-hERRβ does not inhibit hERs through direct Estrogen Response Element (ERE) competition. SF-hERRβ induces no alterations in hERs protein concentrations. SF-hERRβ inhibition of hERs is not through competition/sequestration for PGC-1α, though PGC-1α can be involved. The A/B domain of hERα and the A/B and D domains of SF-hERRβ are required for this inhibition. We determined that SF-hERRβ forms complexes with hERα/hERβ. In addition, DY131, a hERRβ/hERRγ specific agonist can inhibit hER and SF-hERRβ positive human breast cancer MCF-7 cell growth. These findings provide us novel approaches to regulate hERs activities which may lead to discovery of new therapeutic targets for ER-dependent diseases.
